These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27363811)

  • 41. Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.
    Yang J; Zhao R; Feng Q; Zhuo X; Wang R
    Invest New Drugs; 2021 Feb; 39(1):66-76. PubMed ID: 32794135
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipoplexes versus nanoparticles: pDNA/siRNA delivery.
    Khurana B; Goyal AK; Budhiraja A; Aora D; Vyas SP
    Drug Deliv; 2013 Feb; 20(2):57-64. PubMed ID: 23537464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Supramolecular Complex of Methyl-β-cyclodextrin with Adamantane-Grafted Hyaluronic Acid as a Novel Antitumor Agent.
    Elamin KM; Yamashita Y; Higashi T; Motoyama K; Arima H
    Chem Pharm Bull (Tokyo); 2018 Mar; 66(3):277-285. PubMed ID: 29269686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours.
    Evans JC; Malhotra M; Sweeney K; Darcy R; Nelson CC; Hollier BG; O'Driscoll CM
    Int J Pharm; 2017 Oct; 532(1):511-518. PubMed ID: 28916296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Camptothecin-Polysaccharide Co-assembly and Its Controlled Release.
    Yang Y; Zhang YM; Li D; Sun HL; Fan HX; Liu Y
    Bioconjug Chem; 2016 Dec; 27(12):2834-2838. PubMed ID: 27998070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
    Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
    Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enzyme-responsive fluorescent camptothecin prodrug/polysaccharide supramolecular assembly for targeted cellular imaging and in situ controlled drug release.
    Zhang YH; Zhang YM; Sheng X; Wang J; Liu Y
    Chem Commun (Camb); 2020 Jan; 56(7):1042-1045. PubMed ID: 31868189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes.
    Kim SH; Lee SH; Tian H; Chen X; Park TG
    J Drug Target; 2009 May; 17(4):311-7. PubMed ID: 19242850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gold-installed biostable nanocomplexes for tumor-targeted siRNA delivery in vivo.
    Heo R; Yoon HY; Ko H; Shin JM; Jeon J; Chae YS; Kang YM; Kim D; Lee DS; Park JH
    Chem Commun (Camb); 2015 Dec; 51(93):16656-9. PubMed ID: 26426483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles.
    Ganesh S; Iyer AK; Gattacceca F; Morrissey DV; Amiji MM
    J Control Release; 2013 Dec; 172(3):699-706. PubMed ID: 24161254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.
    Shahin SA; Wang R; Simargi SI; Contreras A; Parra Echavarria L; Qu L; Wen W; Dellinger T; Unternaehrer J; Tamanoi F; Zink JI; Glackin CA
    Nanomedicine; 2018 Jun; 14(4):1381-1394. PubMed ID: 29665439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macrocyclic Supramolecular Assemblies Based on Hyaluronic Acid and Their Biological Applications.
    Liu Z; Lin W; Liu Y
    Acc Chem Res; 2022 Dec; 55(23):3417-3429. PubMed ID: 36380600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A bioreducible linear poly(β-amino ester) for siRNA delivery.
    Kozielski KL; Tzeng SY; Green JJ
    Chem Commun (Camb); 2013 Jun; 49(46):5319-21. PubMed ID: 23646347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted decationized polyplexes for siRNA delivery.
    Novo L; Takeda KM; Petteta T; Dakwar GR; van den Dikkenberg JB; Remaut K; Braeckmans K; van Nostrum CF; Mastrobattista E; Hennink WE
    Mol Pharm; 2015 Jan; 12(1):150-61. PubMed ID: 25384057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.
    Lin Q; Jin CS; Huang H; Ding L; Zhang Z; Chen J; Zheng G
    Small; 2014 Aug; 10(15):3072-82. PubMed ID: 24706435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting.
    Yoon HY; Kim HR; Saravanakumar G; Heo R; Chae SY; Um W; Kim K; Kwon IC; Lee JY; Lee DS; Park JC; Park JH
    J Control Release; 2013 Dec; 172(3):653-61. PubMed ID: 24055507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
    Bartlett DW; Davis ME
    Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.
    Xu X; Wu J; Liu Y; Saw PE; Tao W; Yu M; Zope H; Si M; Victorious A; Rasmussen J; Ayyash D; Farokhzad OC; Shi J
    ACS Nano; 2017 Mar; 11(3):2618-2627. PubMed ID: 28240870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel mitochondrial targeting charge-reversal polysaccharide hybrid shell/core nanoparticles for prolonged systemic circulation and antitumor drug delivery.
    Fang L; Zhang W; Wang Z; Fan X; Cheng Z; Hou X; Chen D
    Drug Deliv; 2019 Dec; 26(1):1125-1139. PubMed ID: 31736389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
    Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
    Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.